| It is a series of pathology physiology change vivo which happens, develops and vesting centering on acute Coronary Artery Syndrome. The quite important factor among them is in vivo inflammation reaction. The Interleukin (IL-6) is recognized as the central regulating factor of the inflammation reaction, while the highly sensitive C-reactive protein (CRP) and the tumor necrosis factor (TNF-α) are the main blood marks of inflammation reaction. The reports of statins inchoate intervention on ACS can be seen repeatedly, but there is much dispute over the inchoate intensive treatment of it. The Domestic clinicians'application of statins inclined to small dose generally. This article takes the ACS patient as object of study to determinate serum total cholesterol(TC), low density lipoprotein cholesterin(LDL-C), CRP, IL-6, TNF-α, alanin amino transferase(ALT), aspartic acid amino transferase (AST) and alkalinity phosphatase(AKP), and observe the effects of different dosages of Atorvastatin on ACS patients'viscosity of TC, LDL-C, CRP, IL-6, TNF-α, ALT, AST and AKP of peripheral vascular.Materials and methods:Selecting 92 cases from the patients in hospital diagnosised to be ACS. All the selected candidate accepts the ACS routine treatment, and according to the time of seeing a doctor and the stochastic tables divide them within 48h from overbreaking:Group A (Atorvastatin 10mg) 30 cases, , giving Atorvastatin except for basic and symp-tomless treatment, (the commodity name is Lipitor, pfizer, lot number 55837014,l0mg per pill,sic passim) 10mg/d, to be taken before bedtime;Group B (Atorvastatin 40mg) 31 cases, giving Atorvastatin 40mg/d except for basic treatment, to be taken before bedtime;Group C (contract group) 31 cases, the same to the other two groups except for not giving Atorvastatin. Results:1. Compare the different dosage people treated with medication treats, the blood plasma TC density changes and comparison with the contract group:Before the three groups of patients being treated, the TC density of blood plasma has no obviously difference (P av.>0.05). After the treatment of group B, in 2W, the blood plasma TC density is lower than the determination results of group A and C in the corresponding time period obviously (P av.<0.05).2. Compare the different dosage people treated with medication treats, the blood plasma LDL-C density changes and comparison with the contract group:Before the three groups of patients being treated, the LDL-C density of blood plasma has no obviously difference. After the treatment of group B, in 2W, the blood plasma LDL-C density is lower than the determination results of group A and C in the corresponding time period obviously (P av.<0.05).3. Compare the different dosage people treated with medication treats, the blood plasma IL-6 density changes and comparison with the contract group:Before the three groups of patients being treated, the IL-6 density of blood plasma has no obviously difference. After the treatment of group B, at 3d, in 1W and in 2W, the blood plasma IL-6 density is lower than the determination results of group A and C in the corresponding time period obviously. At the same time, after the treatment of group A, in 2W, the blood plasma IL-6 density is lower than the determination results of group C in the corresponding time period obviously (P av.<0.05~0.01).4. Compare the different dosage people treated with medication treats, the blood plasma CRP density changes and comparison with the contract group:Before the three groups of patients being treated, the CRP density of blood plasma has no obviously difference. After the treatment of group B, at 3d, in 1W and in 2W, the blood plasma CRP density is lower than the determination results of group C in the corresponding time period obviously. At the same time, after the treatment of group B, part index number is lower than the determination results of group A in the corresponding time period. After the treatment of group A, in 2W, the blood plasma CRP density is lower than the determination results of group C in the corresponding time period obviously (P <0.05).Discussion:Some researches discovery that the pathological change plaques transform from the non-activity into the activity causes the serious heart events happen on parts of ACS patients. The acute inflammation responded that during this process played the key role. Simultaneously the radiography material indicated that this part of patients'crown arteries narrow degrees often are mild or moderate, not serious narrow. It illustrate the inflammatory cells activated maybe play an important role in this process. The reports of statins inchoate intervention on ACS can be seen repeatedly, but there is much dispute over the inchoate intensive treatment of it. The Domestic clinicians'application of statins inclined to small dose generally mainly because of the worries about the medicine untoward effect and security. This research (in 48h) gives the different dosage Atorvastatin to 92 cases ACS patient in their early time separately (10mg and 40mg) as well as the conventional anti-cardiac muscle ischemia treatment, and observes 3 groups of ACS patients inflammation (CRP, TNF-a and IL-6) and the indices of safety. The result of this research demonstrations that after taking the different dosages of Atorvastatin 3d, can suppress blood plasma densities of inflammation factors CRP, TNF-a, IL-6 and so on obviously. Simultaneously the improvement of above targets of the cases taking this medicine in big dose is more obvious. That prompts Atorvastatin namely to have the explicit anti-SARS and the stable mottling function in the ACS early time application. And the group in big dose has the more obvious effects. Simultaneously around the patients who use the different dosages to treat in the liver function inspection fore-and-aft the treatment, targets of AKP, AST, ALT and so on have not appeared obviously exceptionally, and also have not discovered the symptoms of allergy, the muscle tenderness and so on. It prompts the ACS patients short-term Atorvastatin strengthening treatment is safe. Some domestic and foreign authors also have the same discovery with us. After they use statins for 3d, then obviously reduces the blood plasma CRP level of ACS patients. The function of Atorvastatin to the blood serum lipin is the competitive inhibition liver cell TC synthesis, while redemptive promotes the LDL-C acceptor's synthesis, in order to accelerate the degeneration of LDL-C. Some literatures report that the effects of Atorvastatin on adjusting the fat are stronger than other statins. These findings also confirmed the short-term Atorvastatin strengthening treatment to have the positive effects to the blood fats control of the ACS patients. After the ACS patients take Atorvastatin of the conventional dosage 10 mg/d for 2W, TC and LDL can be obviously reduced. And the high dose Atorvastatin (40 mg/d) intervening group above accenting fat function to be more obvious. These influences are helpful in the mottling stability and the alleviation condition, and has the obvious curative effects in a short timeConclusion:1. This finding prompts that after taking the different dosages Atorvastatin for 3d, the blood plasma densities of inflammation factors may obviously suppress such as CRP, TNF-a and IL-6 and so on. Simultaneously according to the above targets, the cases taking medicine in big dosage have the more obvious improvements. That prompts Atorvastatin namely to have the explicit anti-SARS and the stable mottling function in the ACS early time application, the big monitoring team curative effects are more obvious. 2. This finding also confirms that when after the ACS patients take 10 mg/d the conventional dosage Atorvastatin for 2W, TC and LDL can be obviously reduced, and the high dose Atorvastatin intervening group (40 mg/d) to above accent fat function to be more obvious.
|
PDF Full Text Request